AI Insight
This entry is a correction notice published in The Lancet regarding a meta-analysis by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) examining the effects of ovarian ablation or suppression on breast cancer recurrence and survival. The original article analyzed patient-level data from approximately 15,000 women across 23 randomized trials. The correction specifies that figures 2 and 3 in the original article have been updated, with the amendment applied to the online version as of May 19, 2026.
Why it matters
Corrections to figures in large-scale meta-analyses are significant because visual data representations directly influence how clinicians and researchers interpret treatment effects for ovarian suppression in breast cancer management. Ensuring the accuracy of published figures is essential for guiding evidence-based decisions in oncology practice.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials. Lancet 2026; 407: 1699–711—In this Article, figure 2 and figure 3 have been updated. This correction has been made to the online version as of May 19, 2026.